MENU

IBRX ImmunityBio Forecast, Technical & Fundamental Analysis

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases... Show more

Industry: #Biotechnology
A.I.Advisor
Nov 10, 2026

ImmunityBio (IBRX) Stock Forecast: What the Push Into Earlier-Stage Bladder Cancer Means Next

Key Takeaways

  • Regulatory momentum is the defining near-term catalyst. ImmunityBio plans to submit a supplemental Biologics License Application (sBLA, a request to expand an approved drug's label) for ANKTIVA in BCG-naïve non-muscle invasive bladder cancer before the end of 2026, potentially opening a materially larger patient population.
  • Strategic positioning is anchored in a first-in-class platform. ANKTIVA is a first-in-class interleukin-15 (IL-15, an immune-signaling protein) receptor agonist that activates natural killer (NK) cells and memory T cells, differentiating it from checkpoint-inhibitor-based immunotherapies.
  • International expansion is broadening the revenue base. The company is scaling a European commercial launch through Accord Healthcare and has secured approvals across roughly 35 countries, reducing dependence on U.S. sales alone.
  • Consensus sentiment is constructive. Analysts broadly rate IBRX a "Strong Buy," with recent price-target increases following the October 2026 label expansion reflecting a more optimistic outlook.
  • Macro sensitivity is concentrated in capital markets. As a cash-consuming biotech, ImmunityBio's funding flexibility is tied to financing conditions and investor risk appetite rather than classic interest-rate or inflation drivers.
  • Key risks include sustained losses. Negative cash flow, a constrained balance sheet, and heavy reliance on a single commercial product could alter the outlook if execution or trial timelines slip.
  • For more context on this ticker's latest developments, explore the dedicated Major News and Today's Price Move pages, review analyst Price Targets, and track upcoming Earnings.
  • To scan for momentum and trading signals across the broader market, explore the Trending AI Robots page.

Strategic Positioning and Competitive Outlook

ImmunityBio occupies a differentiated niche in oncology immunotherapy through its Cancer BioShield platform, built around ANKTIVA (nogapendekin alfa inbakicept). Unlike checkpoint inhibitors that remove brakes on existing T cells, ANKTIVA is designed to activate and expand NK cells and memory T cells, an approach aimed at producing durable immune responses. This mechanistic distinction underpins the company's market positioning in bladder cancer, where ANKTIVA plus BCG (Bacillus Calmette-Guérin, a standard intravesical immunotherapy) is now approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) as well as papillary-only disease.

The medium-term strategy centers on moving ANKTIVA earlier in the treatment journey. Success in the QUILT-2.005 trial in BCG-naïve patients — a larger, first-line population — would meaningfully expand the addressable market and reinforce the company's competitive moat. Beyond bladder cancer, early approvals in non-small cell lung cancer (NSCLC) in Saudi Arabia and a pipeline spanning lymphoma, glioblastoma, and other indications suggest the platform's reach could extend well beyond a single tumor type.

Major Catalysts Ahead

The most significant upcoming event is the planned year-end 2026 sBLA submission for ANKTIVA in BCG-naïve NMIBC, following the QUILT-2.005 trial meeting its primary endpoint. A favorable FDA review would unlock a first-line opportunity that analysts view as the central driver of future upside.

Additional catalysts include regulatory submissions for ANKTIVA plus checkpoint inhibitors in NSCLC across ex-U.S. markets and discussions with the FDA on a potential U.S. accelerated approval pathway, as well as recombinant BCG regulatory filings. Continued execution of the European launch — where the first patients were treated in late 2026 — also matters for near-term revenue visibility.

Analyst sentiment has turned more constructive in response to these developments. Following the October 2026 label expansion, Jefferies raised its price target to $14 from $12, while Piper Sandler lifted its target to $16 from $12, both maintaining Buy ratings; H.C. Wainwright reiterated a $15 target. The consensus recommendation remains a "Strong Buy," with 12-month price targets generally clustering between roughly $12 and $16.

Industry and Macroeconomic Forces

ImmunityBio's trajectory is shaped less by conventional macro variables and more by healthcare-specific dynamics. Reimbursement mechanics, clinical guideline adoption, and physician prescribing patterns in urology practices are the practical forces that will determine whether ANKTIVA converts early-adopter interest into routine use. A permanent J-code for streamlined U.S. billing and recent National Comprehensive Cancer Network guideline updates are supportive structural tailwinds.

On the macro side, interest rates and financing conditions remain relevant because the company is not yet cash-flow positive. Sustained losses, negative equity, and ongoing cash burn mean access to capital markets influences the pace at which ImmunityBio can fund trials and commercial expansion. Broader investor appetite for high-growth, pre-profit biotech equities — often sensitive to shifts in rate expectations and risk sentiment — can therefore amplify volatility in the share price independent of fundamental progress.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. For investors monitoring a high-volatility name like IBRX, the engine can serve as a supplementary signal alongside fundamental and regulatory analysis. Consider exploring the tool to see how its momentum-based outlook compares with your own research.

2026 Outlook and Long-Term Themes to Watch

Looking into 2026 and beyond, the central theme is whether ImmunityBio can convert a promising platform into sustained, profitable scale. The move into BCG-naïve NMIBC represents the clearest structural growth opportunity, as it targets a substantially larger population than the current BCG-unresponsive label. International commercialization across Europe, the Middle East, and other markets provides a second leg of growth, though reimbursement timelines vary by country.

Longer term, cost-structure evolution and margin sustainability will be closely watched. Gross margins on ANKTIVA are high, but the company's cost base remains disproportionate to revenue, and reaching operating profitability will require continued revenue ramp and disciplined spending. Competitive threats, evolving regulatory review timelines, and capital-allocation priorities around pipeline investment versus commercial buildout will shape sentiment. Consensus revenue estimates project continued rapid growth into 2026, but external price targets should be read as analyst expectations rather than forecasts. As ever, the durability of adoption and the timing of the FDA's review of the BCG-naïve filing are the variables most likely to define the stock's future outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

IBRX is expected to report earnings to fall 35.00% to -6 cents per share on March 02

ImmunityBio IBRX Stock Earnings Reports
Q4'26
Est.
$-0.06
Q3'26
Missed
by $0.02
Q2'26
Missed
by $0.14
Q1'26
Missed
by $0.55
Q4'25
Beat
by $0.05
The last earnings report on November 09 showed earnings per share of -10 cents, missing the estimate of -7 cents. With 1.18M shares outstanding, the current market capitalization sits at 9.15B.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AIPO31.23N/A
N/A
Defiance AI & Power Infrastructure ETF
RCLR51.63N/A
N/A
Reckoner BBB-B Clo Reinvesting ETF
COWZ70.51-0.68
-0.96%
Pacer US Cash Cows 100 ETF (COWZ)
NAPR59.44-0.67
-1.12%
Innovator Growth-100 Power Buffer ETF - April (NAPR)
XBOC35.94-0.43
-1.18%
Innovator U.S. Equity Accelerated 9 Buffer ETF - October (XBOC)

IBRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-0.66%
AXON - IBRX
48%
Loosely correlated
-2.85%
ARRY - IBRX
41%
Loosely correlated
-3.51%
QTTB - IBRX
39%
Loosely correlated
-4.82%
NTLA - IBRX
38%
Loosely correlated
+1.65%
FTH - IBRX
37%
Loosely correlated
-7.48%
More
A.I. Advisor
published General Information

General Information

a producer of cancer treatment products

Industry Biotechnology

Industry
Biotechnology
Address
3530 John Hopkins Court
Phone
+1 844 696-5235
Employees
691
Web
https://www.immunitybio.com
ImmunityBio (IBRX) Stock Forecast: What the Push Into Earlier-Stage Bladder Cancer Means Next